WO2001022954A2 - Indolyl-3-glyoxylsäurederivate als antitumormittel - Google Patents
Indolyl-3-glyoxylsäurederivate als antitumormittel Download PDFInfo
- Publication number
- WO2001022954A2 WO2001022954A2 PCT/EP2000/009390 EP0009390W WO0122954A2 WO 2001022954 A2 WO2001022954 A2 WO 2001022954A2 EP 0009390 W EP0009390 W EP 0009390W WO 0122954 A2 WO0122954 A2 WO 0122954A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- groups
- radical
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to the further advantageous embodiment of the German patent application indol-3-glyoxylamide with the file number 19814 838 0
- the metastasis of a tumor is mostly due to poor prognosis
- Tumor treatment accompanied Prerequisite for metastasis is the detachment of cells from the primary tumor, the migration of the cells to the
- MDR gene detected tumor agents such as Vinc ⁇ stin and Taxol also have a not inconsiderable
- the object of the invention is now to expand the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available medicinal product
- the invention relates to the use of N-substituted indole-3-gloxylamides according to claim 1, general formula 1a for tumor treatment, in particular in the case of drug resistance and metastatic carcinoma and for suppressing the formation of metastases, and as an angiogenesis inhibitor,
- R hydrogen, (d -C 6 ) alkyl where the alkyl group one or more times by the
- Phenyl ⁇ ng can be substituted and this Phenyl ⁇ ng in turn one or more times by halogen (d -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl by carboxyl groups, carboxyl groups esterified with Ci -C 6 alkanols T ⁇ fluormethyl phenomenon, hydroxyl groups methoxy groups ethoxy groups benzyloxy groups and can be substituted by a benzyl group substituted one or more times in the phenyl part with (d — C 6 ) alkyl groups, halogen atoms or t ⁇ fluoromethyl groups
- R also stands for the benzyloxycarbonyl group (Z group) and for the tertiary-butoxycarbonyl group (Boc group) for the acetyl group
- Ri can phenylnng, the one or more with (Ci -C 6 ) alkyl (Ci -C 6 ) alkoxy, cyano, halogen, T ⁇ fluormethyl, hydroxy, benzyloxy nitro amino (Ci -C 6 ) alkylam, (C 1 -C 6 ) Alkoxycarbonylam ⁇ no and with Carboxyl group or substituted with the carboxyl group esterified with Ci -C 6 alkanols, or a Py ⁇ dm skeleton of formula 2 and its N-oxide
- the Py ⁇ din skeleton is optionally bonded to the ring carbon atoms 2, 3 and 4 and can be substituted with the substituents R 5 and R 6.
- the radicals R 5 and R 6 can be the same or different and the Meaning (Ci -C 6 ) alkyl and the meaning (C 3 -C 7 ) cycloalkyl, (d -C 6 ) alkoxy, nitro, amino, hydroxy, halogen and trifluoromethyl and also the ethoxycarbonylamino radical and the group Represent carboxyalkyloxy in which the alkyl group can have 1 -4 C atoms can also be a 2- or 4-py ⁇ m ⁇ d ⁇ nyl heterocycle, where the 2-py ⁇ midinyl ring can be substituted one or more times with the methyl group, furthermore with (Ci-C 6 ) alkyl, halogen, the nitro group of the amino group and the (C 1 -C 6 ) -alkyl-
- Ce-alkanols for example as methyl, ethyl or as tert-butyl ester.
- R-, the allylaminocarbonyl-2-methyl-prop-1-yl group can mean R and Ri can also together with the nitrogen atom, to which they are bound, a piperazm ⁇ ng of formula 3 or one
- Ri represents an aminoalkylene group in which
- R 7 represents an alkyl radical, denotes a phenylene which has one or more radicals with (d -C 6 ) alkyl, (Ci -C 6 ) alkoxy, halogen, the nitro group, the amino function and with the (d -C 6 ) -Alkylam ⁇ noè can be substituted
- R 7 also means the benzhydryl group and the bis-p-fluorobenzylhydryl group
- R 2 may be hydrogen and (Ci-C6) alkyl group, wherein the alkyl group is mono- or polysubstituted by halogen and phenyl, which for its part or polysubstituted by halogen, (Ci-C6) alkyl, (C 3 -
- C 7 -cycloalkyl, carboxyl groups which are esterified with Ci-C-alkanols, carboxyl groups, t ⁇ fluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups or benzyloxy groups.
- the (dC 6 ) -alkyl group applicable to R 2 can also be substituted by the 2-quinolyl group and the 2-, 3- and 4-pyridyl skeleton can be substituted, both of which can each be substituted one or more times by halogen, (Ci-C 4 ) alkyl groups or (Ci - C 4 ) alkoxy groups
- R 2 is also for the aroyl radical, the aryl part on which this radical is based
- Phenyl ring which is single or multiple halogen, (Ci -C 6 ) -
- Methoxy groups, ethoxy groups or benzyloxy groups can be substituted
- R 3 and R 4 may be the same or different and are hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) cycloalkyl, (C 1 -C 6 ) alkanoyl, (C 1 -C 3 ) alkoxy, Halogen and benzyloxy may furthermore mean R 3 and R the nitro group, the amino group, the (Ci-C 4 ) -mono- or dialkyl-substituted amino group, and the (Ci-C 6 ) - alkoxy-carbonylamino function or (Ci-C 6 ) -Alkoxycarbonylam ⁇ no- (d -C 6 ) - alkyl function Z stands for O and S
- alkyl, alkanol, alkoxy or alkylamino group for the radicals R, R 1, R 7 , R 3 , R 4 , Rs, R 6 , R 7 regularly means both “straight-chain” and “branched” aikyl groups where “straight-chain alkyl groups” can mean, for example, residues such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and “branched alkyl groups” denote, for example, residues such as isopropyl or tert-butyl.
- Cycloalkyl refers to residues such as for example to understand cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl
- halogen stands for fluorine, chlorine, bromine or iodine.
- alkoxy group represents residues such as methoxy, ethoxy propoxy, butoxy, isopropoxy, isobutoxy or pentoxy
- the compounds can also be used as acid addition salts, for example as salts of mineral acids, such as hydrochloric acid,
- Sulfuric acid, phosphoric acid, salts of organic acids such as, for example, acetic acid, lactic acid, malonic acid, maleic acid, fumaric acid, gluconic acid,
- the compounds of formula 1 can be administered in free form or as salts with physiologically acceptable acids
- the application can be carried out orally, parenterally, intravenously, transdermally or by inhalation.
- the invention further relates to pharmaceutical preparations with a
- Suitable forms of administration are, for example, tablets, dragees, capsules, solutions for infusion or ampoules, suppositons, plasters, inhalable powder preparations, suspensions, creams and ointments
- D-24851 (see claim 4) on the MDR (multidrug resistant) leukemia cell line of the mouse L 1210A / CR is not influenced in vivo and in vitro. See FIGS. 1, 2 and 3 D-24851 (see claim 4) has an unchanged cytotoxic activity against the multidrug-resistant mouse leukemia cell sublime L1210A CR in contrast to taxol, doxirubicin, Vinc ⁇ stin or Epotholon B
- the mouse leukemia cell L 1210 was adapted to Vinc ⁇ stin.
- the non-adapted (L1210) and the adapted (L1210A / CR) cells were exposed to cytostatic agents and the cell growth, which was determined by the metabolic activity, was determined (XTT test).
- D-24 851 (see claim 4) inhibits the migration of MO4 cells in a dose-dependent manner.
- An anti-invasive and an antimetastatic effect can be derived from this for D-24851
- MO4 cells The migration ability of MO4 cells can be measured in vitro by
- FIG. 4 shows that the migration of the cells decreases with increasing D-24851 concentration.
- D-24851 shows both the migration as well as inhibiting the invasion of tumor cells and thus having a strong antimetastastic potential
- D-24851 has significantly fewer side effects than other chemotherapeutic agents
- Angiognese inhibitors are due to the physiological relationship to
- Tumor growth is also a means of inhibiting tumor growth by inhibiting the formation of new blood vessels that are intended to feed the tumor
- D-24851 causes an in vitro antiangiogenesis model on endothelial cells to completely inhibit vascularization, which is not due to a cytotoxic
- the cells came from human umbilical vein (arterial function). They were used in the third and fourth passages for the examination.
- Angiogenesis is triggered by a natural stimulus.
- the primary trigger of endothehal migration is a protein that is increasingly exposed in vascular tissue. The substances become the culture medium added just before the induction of angiogenesis
- D-24851 concentration for the antiangiogenic effect of D-24851 is clearly below the concentration for the cytotoxic activity. It is thus possible to separate the two action qualities (cytotoxic activity and antiangiogenic effect) from one another
- the invention also encompasses the use of the N-substituted indole-3-gloxylamides according to claim 1, general formula 1 a in further diseases in which an angiogense inhibitory effect is functionally required (eg wound healing)
- the invention also relates to the fixed or free combination of the N-substituted indole-3-gloxylamides according to claim 1, general formula 1a with antitumor agents known per se, and the replacement of antitumor agents which have become ineffective as a result of resistance development by N-substituted indole-3- gloxylamiden according to claim 1 general formula 1 a
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001526166A JP2003510274A (ja) | 1999-09-28 | 2000-09-26 | 治療上重要な特性を有するインドリル−3−グリオキシル酸誘導体 |
DE50015879T DE50015879D1 (de) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylsäure-derivate mit therapeutisch wertvollen eigenschaften |
AT00967789T ATE459356T1 (de) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylsäure-derivate mit therapeutisch wertvollen eigenschaften |
PL364811A PL199576B1 (pl) | 1999-09-28 | 2000-09-26 | Zastosowanie jednego lub więcej N-podstawionych indolo-3-glioksylamidów lub ich fizjologicznie tolerowanych soli addycyjnych do wytwarzania leku do leczenia farmaceutycznie opornych nowotworów |
BR0014378-2A BR0014378A (pt) | 1999-09-28 | 2000-09-26 | Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas |
HU0202788A HUP0202788A3 (en) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylic acid derivatives serving as antitumor agents and pharmaceutical compositions containing them |
AU77829/00A AU783436B2 (en) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties |
NZ517988A NZ517988A (en) | 1999-09-28 | 2000-09-26 | Antitumour compositions comprising indolyl-3-glyoxylic acid derivatives |
KR1020027003937A KR100759242B1 (ko) | 1999-09-28 | 2000-09-26 | 치료학적으로 유용한 인돌릴-3-글리옥실산 유도체 |
EEP200200169A EE200200169A (et) | 1999-09-28 | 2000-09-26 | Terapeutiliselt väärtuslike omadustega indolüül-3-glüoksüülhappe derivaadid |
YUP-227/02A RS51302B (sr) | 1999-09-28 | 2000-09-26 | Derivati indolil-3-glioksilne kiseline sa terapeutski vrednim svojstvima |
CA2386069A CA2386069C (en) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylic acid derivatives as antitumor agents |
EP00967789A EP1218006B1 (de) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylsäure-derivate mit therapeutisch wertvollen eigenschaften |
SK407-2002A SK287533B6 (sk) | 1999-09-28 | 2000-09-26 | Liečivo na liečenie viacpočetných rezistentných nádorov alebo na inhibíciu angiogenézy a metastáz |
UA2002043433A UA75872C2 (en) | 1999-09-28 | 2000-09-26 | Indolyl-3- glyoxylic acid with useful therapeutic properties |
MXPA02002824A MXPA02002824A (es) | 1999-09-28 | 2000-09-26 | Derivados del acido indolin-2-glioxilico que comprenden propiedades terapeuticamente valiosas. |
IL14867000A IL148670A0 (en) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties |
IL148670A IL148670A (en) | 1999-09-28 | 2002-03-13 | Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties |
NO20021367A NO322614B1 (no) | 1999-09-28 | 2002-03-19 | Indolyl-3-glykosylsyrederivater som har terapeutisk verdifulle egenskaper |
IS6319A IS6319A (is) | 1999-09-28 | 2002-03-21 | Indólýl-3-glýoxý sýru afleiður sem innihalda gagnlega meðferðarlega eiginleika |
BG106639A BG106639A (bg) | 1999-09-28 | 2002-04-23 | Производни на индолил-3-глиоксилова киселина с терапевтично значими свойства |
HR20020369A HRP20020369A2 (en) | 1999-09-28 | 2002-04-26 | Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties |
HK03101178.9A HK1048941B (zh) | 1999-09-28 | 2003-02-18 | 具有治療學有用性質的吲哚基-3-乙醛酸衍生物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19946301A DE19946301A1 (de) | 1998-04-02 | 1999-09-28 | Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften |
DE19946301.8 | 1999-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001022954A2 true WO2001022954A2 (de) | 2001-04-05 |
WO2001022954A3 WO2001022954A3 (de) | 2002-03-28 |
Family
ID=7923485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/009390 WO2001022954A2 (de) | 1999-09-28 | 2000-09-26 | Indolyl-3-glyoxylsäurederivate als antitumormittel |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1218006B1 (de) |
JP (1) | JP2003510274A (de) |
KR (1) | KR100759242B1 (de) |
CN (1) | CN1301712C (de) |
AR (1) | AR025885A1 (de) |
AT (1) | ATE459356T1 (de) |
AU (1) | AU783436B2 (de) |
BG (1) | BG106639A (de) |
BR (1) | BR0014378A (de) |
CA (1) | CA2386069C (de) |
CZ (1) | CZ303246B6 (de) |
DE (1) | DE50015879D1 (de) |
DZ (1) | DZ3196A1 (de) |
EE (1) | EE200200169A (de) |
ES (1) | ES2342042T3 (de) |
GE (1) | GEP20043250B (de) |
HK (1) | HK1048941B (de) |
HR (1) | HRP20020369A2 (de) |
HU (1) | HUP0202788A3 (de) |
IL (2) | IL148670A0 (de) |
IS (1) | IS6319A (de) |
MX (1) | MXPA02002824A (de) |
NO (1) | NO322614B1 (de) |
NZ (1) | NZ517988A (de) |
PL (1) | PL199576B1 (de) |
RS (1) | RS51302B (de) |
RU (1) | RU2282444C2 (de) |
SK (1) | SK287533B6 (de) |
TW (1) | TWI269654B (de) |
UA (1) | UA75872C2 (de) |
WO (1) | WO2001022954A2 (de) |
ZA (1) | ZA200202556B (de) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047913A2 (de) * | 1999-12-23 | 2001-07-05 | Zentaris Ag | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung |
WO2002010152A2 (de) * | 2000-07-28 | 2002-02-07 | Zentaris Ag | Neue indolderivate und deren verwendung als arzneimittel |
EP1484329A1 (de) * | 2003-06-06 | 2004-12-08 | Zentaris GmbH | Indolderivate mit Apoptose induzierender Wirkung |
WO2004108702A1 (de) * | 2003-06-05 | 2004-12-16 | Zentaris Gmbh | Indolderivate mit apoptose induzierender wirkung |
EP1595878A1 (de) * | 2004-05-15 | 2005-11-16 | Zentaris GmbH | Indolderivate mit Apoptose induzierender Wirkung |
US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
EP2091532A1 (de) * | 2006-11-28 | 2009-08-26 | Ziopharm Oncology, Inc. | Verwendung von indolyl-3-glyoxylsäure-derivaten einschliesslich indibulin, allein oder in kombination mit weiteren mitteln zur behandlung von krebs |
US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
US7829711B2 (en) | 2004-11-09 | 2010-11-09 | Bristol-Myers Squibb Company | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione |
US7851476B2 (en) | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
US7902204B2 (en) | 2003-11-26 | 2011-03-08 | Bristol-Myers Squibb Company | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US9000007B2 (en) | 2011-09-27 | 2015-04-07 | Dr. Reddy's Laboratories Ltd. | 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
CN109111501A (zh) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 脂肪氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 |
US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US10918735B2 (en) | 2012-12-04 | 2021-02-16 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US12030888B2 (en) | 2021-12-23 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103356636A (zh) * | 2004-05-23 | 2013-10-23 | 杰勒德·M·豪斯 | Theramutein调节剂 |
MX2007005434A (es) * | 2004-11-08 | 2007-07-10 | Baxter Int | Composiciones de nanoparticulado de inhibidor de tubulina. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636150A1 (de) * | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
WO1999046237A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
WO1999051224A1 (de) * | 1998-04-02 | 1999-10-14 | Asta Medica Aktiengesellschaft | Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung |
WO1999055696A1 (de) * | 1998-04-28 | 1999-11-04 | Arzneimittelwerk Dresden Gmbh | Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung |
JP2000239252A (ja) * | 1999-02-16 | 2000-09-05 | Mitsubishi Chemicals Corp | インドール誘導体 |
WO2000067802A1 (en) * | 1999-05-10 | 2000-11-16 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
WO1994008581A1 (en) * | 1992-10-20 | 1994-04-28 | Toray Industries, Inc. | Eosinophil infiltration inhibitor |
AU6523598A (en) | 1997-04-08 | 1998-10-30 | Banyu Pharmaceutical Co., Ltd. | Cancerous metastasis-associated gene |
PL343007A1 (en) * | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
-
2000
- 2000-09-22 TW TW089119680A patent/TWI269654B/zh not_active IP Right Cessation
- 2000-09-26 CA CA2386069A patent/CA2386069C/en not_active Expired - Fee Related
- 2000-09-26 NZ NZ517988A patent/NZ517988A/en not_active IP Right Cessation
- 2000-09-26 SK SK407-2002A patent/SK287533B6/sk not_active IP Right Cessation
- 2000-09-26 DE DE50015879T patent/DE50015879D1/de not_active Expired - Lifetime
- 2000-09-26 DZ DZ003196A patent/DZ3196A1/xx active
- 2000-09-26 JP JP2001526166A patent/JP2003510274A/ja active Pending
- 2000-09-26 CN CNB008134499A patent/CN1301712C/zh not_active Expired - Fee Related
- 2000-09-26 GE GEAP20006425A patent/GEP20043250B/en unknown
- 2000-09-26 CZ CZ20021005A patent/CZ303246B6/cs not_active IP Right Cessation
- 2000-09-26 AU AU77829/00A patent/AU783436B2/en not_active Ceased
- 2000-09-26 ES ES00967789T patent/ES2342042T3/es not_active Expired - Lifetime
- 2000-09-26 HU HU0202788A patent/HUP0202788A3/hu unknown
- 2000-09-26 EP EP00967789A patent/EP1218006B1/de not_active Expired - Lifetime
- 2000-09-26 EE EEP200200169A patent/EE200200169A/xx unknown
- 2000-09-26 AT AT00967789T patent/ATE459356T1/de not_active IP Right Cessation
- 2000-09-26 RS YUP-227/02A patent/RS51302B/sr unknown
- 2000-09-26 WO PCT/EP2000/009390 patent/WO2001022954A2/de active IP Right Grant
- 2000-09-26 IL IL14867000A patent/IL148670A0/xx unknown
- 2000-09-26 UA UA2002043433A patent/UA75872C2/uk unknown
- 2000-09-26 MX MXPA02002824A patent/MXPA02002824A/es active IP Right Grant
- 2000-09-26 RU RU2002111866/15A patent/RU2282444C2/ru not_active IP Right Cessation
- 2000-09-26 BR BR0014378-2A patent/BR0014378A/pt not_active Application Discontinuation
- 2000-09-26 KR KR1020027003937A patent/KR100759242B1/ko not_active IP Right Cessation
- 2000-09-26 PL PL364811A patent/PL199576B1/pl not_active IP Right Cessation
- 2000-09-28 AR ARP000105105A patent/AR025885A1/es unknown
-
2002
- 2002-03-13 IL IL148670A patent/IL148670A/en not_active IP Right Cessation
- 2002-03-19 NO NO20021367A patent/NO322614B1/no not_active IP Right Cessation
- 2002-03-21 IS IS6319A patent/IS6319A/is unknown
- 2002-04-02 ZA ZA200202556A patent/ZA200202556B/en unknown
- 2002-04-23 BG BG106639A patent/BG106639A/bg unknown
- 2002-04-26 HR HR20020369A patent/HRP20020369A2/hr not_active Application Discontinuation
-
2003
- 2003-02-18 HK HK03101178.9A patent/HK1048941B/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636150A1 (de) * | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
WO1999046237A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
WO1999051224A1 (de) * | 1998-04-02 | 1999-10-14 | Asta Medica Aktiengesellschaft | Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung |
WO1999055696A1 (de) * | 1998-04-28 | 1999-11-04 | Arzneimittelwerk Dresden Gmbh | Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung |
JP2000239252A (ja) * | 1999-02-16 | 2000-09-05 | Mitsubishi Chemicals Corp | インドール誘導体 |
WO2000067802A1 (en) * | 1999-05-10 | 2000-11-16 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 12, 3. Januar 2001 (2001-01-03) & JP 2000 239252 A (MITSUBISHI CHEMICALS CORP.), 5. September 2000 (2000-09-05) * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047913A2 (de) * | 1999-12-23 | 2001-07-05 | Zentaris Ag | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung |
WO2001047913A3 (de) * | 1999-12-23 | 2002-04-25 | Zentaris Ag | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung |
US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US7365081B2 (en) | 2000-07-28 | 2008-04-29 | Aeterna Zentaris Gmbh | Indole derivatives and their use as medicaments |
JP2004505075A (ja) * | 2000-07-28 | 2004-02-19 | ツェンタリス アクチエンゲゼルシャフト | 新規のインドール誘導体および医薬としてのその使用 |
CZ304197B6 (cs) * | 2000-07-28 | 2013-12-27 | Zentaris Gmbh | Indolový derivát, způsob jeho přípravy a léčivo s jeho obsahem |
WO2002010152A3 (de) * | 2000-07-28 | 2002-08-01 | Zentaris Ag | Neue indolderivate und deren verwendung als arzneimittel |
WO2002010152A2 (de) * | 2000-07-28 | 2002-02-07 | Zentaris Ag | Neue indolderivate und deren verwendung als arzneimittel |
EP1939195A1 (de) * | 2000-07-28 | 2008-07-02 | AEterna Zentaris GmbH | Neue Indolderivate und deren Verwendung als Arzneimittel |
US8008324B2 (en) | 2000-07-28 | 2011-08-30 | Aeterna Zentaris Gmbh | Indole derivatives and their use as medicament |
EP2163552A1 (de) * | 2000-07-28 | 2010-03-17 | AEterna Zentaris GmbH | Indolderivate und deren Verwendung als Antitumormittel |
US7989453B2 (en) | 2000-07-28 | 2011-08-02 | Aeterna Zentaris Gmbh | Indole derivatives and their use as medicament |
WO2004108702A1 (de) * | 2003-06-05 | 2004-12-16 | Zentaris Gmbh | Indolderivate mit apoptose induzierender wirkung |
EP1484329A1 (de) * | 2003-06-06 | 2004-12-08 | Zentaris GmbH | Indolderivate mit Apoptose induzierender Wirkung |
US7902204B2 (en) | 2003-11-26 | 2011-03-08 | Bristol-Myers Squibb Company | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
EP1595878A1 (de) * | 2004-05-15 | 2005-11-16 | Zentaris GmbH | Indolderivate mit Apoptose induzierender Wirkung |
US7829711B2 (en) | 2004-11-09 | 2010-11-09 | Bristol-Myers Squibb Company | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US9782407B2 (en) | 2004-12-31 | 2017-10-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US7851476B2 (en) | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
EP2091532A1 (de) * | 2006-11-28 | 2009-08-26 | Ziopharm Oncology, Inc. | Verwendung von indolyl-3-glyoxylsäure-derivaten einschliesslich indibulin, allein oder in kombination mit weiteren mitteln zur behandlung von krebs |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
US9000007B2 (en) | 2011-09-27 | 2015-04-07 | Dr. Reddy's Laboratories Ltd. | 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
US10918735B2 (en) | 2012-12-04 | 2021-02-16 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment |
US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CN109111501A (zh) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 脂肪氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 |
CN109111501B (zh) * | 2017-06-23 | 2022-04-22 | 首都医科大学 | 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成,活性和应用 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
US12030888B2 (en) | 2021-12-23 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001022954A2 (de) | Indolyl-3-glyoxylsäurederivate als antitumormittel | |
DE19814838C2 (de) | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung | |
DE19946301A1 (de) | Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften | |
DE60208385T2 (de) | Antineoplastische kombinationspräparate | |
CA2559282A1 (en) | Methods for the treatment of synucleinopathies | |
DE3319347A1 (de) | Arzneimittel zur verstaerkung der therapeutischen wirkung von antitumormitteln und deren verwendung | |
EP1397138A2 (de) | Wirkstoff-kombination zur medikamentösen sucht- oder rauschmitteltherapie | |
DE60225943T2 (de) | Topoisomerase-giftmittel | |
DE69920455T2 (de) | Bis-indolederivate und ihre verwendung als entzündungshemmende mittel | |
DE60123117T2 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
EP0334243B1 (de) | Arzneimittel enthaltend Aminoacridine zur iontophoretischen Behandlung von Carcinomen | |
CH660556A5 (de) | Therapeutische zubereitung zur behandlung von kardiovaskulaeren krankheiten. | |
DE69814089T2 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung | |
Lyttkens et al. | Local anaesthetics and tinnitus: proposed peripheral mechanism of action of lidocaine | |
DE10163421A1 (de) | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum | |
DE69735383T2 (de) | Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen | |
DE60210329T2 (de) | Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren | |
EP1605952B1 (de) | Verwendung von 5-substituierten nukleosiden zur verstärkung der apoptotischen wirkung von zytostatika | |
EP0623350A1 (de) | Verwendung von Bradykinin-Antagonisten zur Herstellung eines Medikaments zur Prophylaxe oder zum Behandeln der Arteriosklerose | |
WO1999066931A1 (de) | Verwendung von 1-(aminoalkyl)-3-chinoxalin-2-on-derivaten zur herstellung von als antioxidantien wirkenden zusammensetzungen | |
DE4442257A1 (de) | Sparsomycin | |
DE102004056727A1 (de) | Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel | |
DE496796T1 (de) | Verfahren und zubereitungen zur hemmung von mit oxidativer schaedigung assoziierten krankheiten. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-227/02 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 148670 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002824 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-1005 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4072002 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2001 526166 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 517988 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027003937 Country of ref document: KR Ref document number: IN/PCT/2002/399/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2386069 Country of ref document: CA Ref document number: 008134499 Country of ref document: CN Ref document number: 2002/00815 Country of ref document: TR |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000967789 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/02556 Country of ref document: ZA Ref document number: 200202556 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2000 106639 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 77829/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20020369A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002111866 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2000967789 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027003937 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-1005 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 517988 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 517988 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 77829/00 Country of ref document: AU |